Lauren Pilato
Acute Care · Stony Brook, NYNPI 1760823413
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.8% of the total across 144 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by Abbott at 58.5% of the total. Among acute care clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 144 payments — averaging $44.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$4K
- Vifor Pharma, Inc.$525
- Novartis$345
- E.r. Squibb & Sons, L.L.C.$326
- AstraZeneca$267
- Endotronix, Inc.$211
- plus $974 from 11 others
What the payments were for
- Speaking & faculty fees$5258%
- Food & beverage$5,85692%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 84 | $3,732 |
| Vifor Pharma, Inc. | 1 | $525 |
| Novartis | 16 | $345 |
| E.r. Squibb & Sons, L.L.C. | 8 | $326 |
| AstraZeneca | 4 | $267 |
| Endotronix, Inc. | 1 | $211 |
| Impulse Dynamics (USA) Inc. | 2 | $191 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $170 |
| Scpharmaceuticals Inc. | 6 | $154 |
| Regeneron Healthcare Solutions, Inc. | 4 | $104 |
| Merck | 5 | $86 |
| Alnylam Pharmaceuticals Inc. | 3 | $80 |
| Lexicon Pharmaceuticals, Inc. | 2 | $52 |
| Pfizer | 2 | $45 |
| United Therapeutics Corporation | 2 | $39 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $28 |
| Amgen | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CARDIOMEMS$2,149
- Veltassa$525
- OPTIMIZER$343
- FARXIGA$238
- CAMZYOS$225
- CORDELLA PULOMONARY ARTERY PRESSURE SENSOR$211
- CardioMEMS HF System$123
- MitraClip$116
How this compares
$6,381 in reported general payments places this provider in the 95th percentile of 980 acute care providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 66 | $1,951,142 |
| Tyvaso DpiTreprostinil | 16 | $383,505 |
| OpsumitMacitentan | 12 | $153,841 |
| EntrestoSacubitril/Valsartan | 95 | $151,142 |
| FarxigaDapagliflozin Propanediol | 60 | $90,641 |
| CamzyosMavacamten | 11 | $84,149 |
| JardianceEmpagliflozin | 57 | $74,781 |
| EliquisApixaban | 33 | $43,917 |
| LokelmaSodium Zirconium Cyclosilicate | 20 | $21,347 |
| XareltoRivaroxaban | 12 | $8,942 |
| Metoprolol Succinate | 127 | $2,136 |
| Eplerenone | 21 | $2,126 |
| Torsemide | 64 | $1,863 |
| Valsartan | 29 | $1,125 |
| Spironolactone | 153 | $1,108 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $45 | $1,995,06099 claims |
| NovartisEntresto | $345 | $151,14295 claims |
| AstraZenecaFarxiga, Lokelma | $267 | $111,98880 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $326 | $84,14911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 980 acute care providers in New York.
Other acute care in Stony Brook
- Chrysa SmalleyStony Brook$4K
- Daniel VerinaNew York$464K
- Michele BiscossiSaratoga Springs$64K
- Heidi YipCanandaigua$29K
- Katie WorthingtonNew York$25K
- Loveth AdenugaNew York$20K
- Katherine DukeNew York$18K
- Ann HarrisBrooklyn$14K
- Marcel RozarioMedina$10K
- Julie Anne RoldanNew York$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.